Arax Advisory Partners’s Pacific Biosciences PACB Stock Holding History

Arax Advisory Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.9K	Buy	17,775 +15,642	+733%	+$22.7K	﹤0.01%	3678
2026 Q1	$2.82K	Buy	2,133 +121	+6%	+$216	﹤0.01%	3004
2025 Q4	$3.76K	Sell	2,012 -1,085	-35%	-$2.08K	﹤0.01%	3000
2025 Q3	$3.96K	Buy	3,097 +1,097	+55%	+$1.49K	﹤0.01%	2936
2025 Q2	$2.48K	Buy	2,000 +1,000	+100%	+$1.16K	﹤0.01%	2488
2025 Q1	$1.18K	Hold	1,000	–	–	﹤0.01%	2254
2024 Q4	$1.83K	Sell	1,000 -1,000	-50%	-$1.95K	﹤0.01%	2028
2024 Q3	$3.4K	Buy	2,000 +1,000	+100%	+$1.64K	﹤0.01%	1873
2024 Q2	$1.37K	Hold	1,000	–	–	﹤0.01%	2083
2024 Q1	$3.75K	Hold	1,000	–	–	﹤0.01%	957
2023 Q4	$9.81K	Buy	1,000 +500	+100%	+$4.09K	﹤0.01%	762
2023 Q3	$4.17K	Buy	+500	New	+$5.71K	﹤0.01%	914

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's PACB Position: Q2 2026 in Review

Arax Advisory Partners increased its Pacific Biosciences (PACB) stake by 733% in Q2 2026, buying an estimated $22.7K and bringing the position to 17,775 shares worth $29.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3678.

Arax Advisory Partners first reported a position in PACB in Q3 2023 and has held it in 12 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Arax Advisory Partners held 17,775 shares of Pacific Biosciences worth $29.9K as of Q2 2026.
Arax Advisory Partners bought 15,642 Pacific Biosciences shares in Q2 2026, an estimated $22.7K.
Pacific Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3678 holding.
Arax Advisory Partners first reported a position in Pacific Biosciences in Q3 2023 and has held it in 12 quarters since.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.